Metastatic Breast Cancer Clinical Trials in Birmingham, Alabama

7 studies are recruiting for metastatic breast cancer in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. PRE-ISPY Phase I/II Oncology Platform Program

   PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama

   Locations

   10 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT05868226 on ClinicalTrials.gov

2. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

   The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HE…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama, Birmingham, Alabama

   Locations

   11 in total

   Run by

   Ana C Garrido-Castro, MD

   See if you can join NCT06533826 on ClinicalTrials.gov

3. A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

   PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines o…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Alabama Oncology, Birmingham, Alabama

   Locations

   53 in total

   Run by

   Puma Biotechnology, Inc.

   See if you can join NCT06369285 on ClinicalTrials.gov

4. Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

   This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast cancer (MBC) participating in the Promoting Resilience in Women with Breast Cancer (PRISM) intervent…

   Stage

   Not phased

   Ages

   18 and older

   Site

   The University of Alabama, Birmingham, Alabama

   Locations

   2 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT06855654 on ClinicalTrials.gov

5. A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

   The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   12 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06099769 on ClinicalTrials.gov

6. Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

   This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama Birmingham, Birmingham, Alabama

   Locations

   3 in total

   Run by

   Sonya Reid

   See if you can join NCT05693766 on ClinicalTrials.gov

7. Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

   This is a phase II study aiming at evaluating capecitabine prospectively at a dose of 1000 mg once daily in patients with advanced breast cancer who are ≥60 years of age, or frail at any age, with a greater risk of complications and poorer outcomes with other treatments.

   Stage

   Phase 2

   Ages

   60 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT06105684 on ClinicalTrials.gov